Back to top
more

XOMA Corporation (XOMA)

(Delayed Data from NSDQ)

$18.69 USD

18.69
38,708

+0.44 (2.41%)

Updated Sep 24, 2020 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.33%
2Buy17.77%
3Hold9.37%
4Sell4.88%
5Strong Sell1.79%
S&P50010.56%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 23% (193 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Zacks Equity Research

XOMA's Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in XOMA.

Zacks Equity Research

Xoma (XOMA) Reports Q2 Loss, Lags Revenue Estimates

Xoma (XOMA) delivered earnings and revenue surprises of 13.16% and -74.77%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

XOMA (XOMA) Catches Eye: Stock Jumps 5.2%

XOMA (XOMA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Zacks Equity Research

Xoma (XOMA) Reports Q1 Loss, Lags Revenue Estimates

Xoma (XOMA) delivered earnings and revenue surprises of -206.25% and -76.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Xoma (XOMA) Q1 Earnings Expected to Decline

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Will XOMA Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in XOMA.

Zacks Equity Research

5 Biotech Stocks Set for Continued Rally in 2020

The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.

Zacks Equity Research

Will XOMA Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor XOMA.

Zacks Equity Research

Will Xoma (XOMA) Report Negative Q3 Earnings? What You Should Know

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Xoma (XOMA) Reports Q2 Loss, Tops Revenue Estimates

Xoma (XOMA) delivered earnings and revenue surprises of 14.55% and 52.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Xoma (XOMA) to Report a Decline in Earnings: What to Look Out for

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Benjamin Rains

A Firm's First Profit Can Mean Big Returns for Investors

We are already roughly halfway through second-quarter 2019 earnings season. This means now could be a great time to look at a 'First Profit' stock screen.

Zacks Equity Research

Xoma (XOMA) Surpasses Q1 Earnings and Revenue Estimates

Xoma (XOMA) delivered earnings and revenue surprises of 261.54% and 152.12%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Xoma (XOMA) Report Negative Q1 Earnings? What You Should Know

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Agenus (AGEN) Q3 Loss Wider Than Expected, Pipeline in Focus

Agenus (AGEN) reports a wider third-quarter loss. Revenues earned from collaborations exceeded expectations.

Zacks Equity Research

Xoma (XOMA) Reports Q3 Loss, Tops Revenue Estimates

Xoma (XOMA) delivered earnings and revenue surprises of -44.74% and 7.95%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Xoma (XOMA) Q3 Earnings Preview: What's Shaping Up?

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Xoma (XOMA) Reports Q2 Loss, Lags Revenue Estimates

Xoma (XOMA) delivered earnings and revenue surprises of -15.00% and -50.60%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AbbVie Presents New Data on Upadacitinib for Crohn's Disease

AbbVie (ABBV) announces new data from a phase II study on upadacitinib in adult patients with moderately to severely active Crohn's disease.

Zacks Equity Research

Acorda (ACOR) Q4 Earnings Miss Estimates, Revenues Beat

Acorda (ACOR) misses on earnings in Q4 but beats on revenue estimates. The company's key drug Ampyra witnesses an increase in sales both year over year and sequentially.

Zacks Equity Research

FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review

FDA accepts Agios' NDA for its pipeline candidate ivosidenib (AG-120) and sets an action date of Aug 21, 2018.

Zacks Equity Research

Ironwood (IRWD) Beats Estimates in Q4 Earnings, Stock Up

Ironwood Pharmaceuticals (IRWD) beats estimates on both counts in the fourth quarter. Demand for Linzess continues to rise.

Zacks Equity Research

Alkermes (ALKS) Beats Q4 Earnings, Revenue Estimates

Alkermes (ALKS) tops earnings and sales estimates in the fourth quarter of 2017 on the back of strong growth of Vivitrol and Aristada. The company provided a decent outlook for 2018.